Skip to main content

Regino Gonzalez-Peralta, MD

Regino Gonzalez-Peralta , MD

Pediatric Gastroenterologist

Pediatrics

Regino Gonzalez-Peralta

Overview

Regino Gonzalez-Peralta, MD, is a board-certified pediatric gastroenterologist with additional board certification in pediatric transplant hepatology. Prior to joining AdventHealth Medical Group, he served as a tenured pediatrics professor, assistant dean and director of pediatric hepatology at the University of Florida and concurrently served as a pediatric hepatologist at Arnold Palmer Hospital for Children. A native of Cuba, Dr. Gonzalez-Peralta grew up in Miami and attended Cornell University before pursuing his medical degree at the Universidad Central del Este (Dominican Republic). He undertook his pediatrics residency at Cook County Hospital in Chicago, and continued as Senior Resident and Co-Chief Resident at the University of Florida before being selected for a prestigious fellowship in pediatric gastroenterology. His clinical and research interests include childhood HBV and HCV infection, pediatric liver transplant, Wilson disease, alpha 1 antitrypsin deficiency, pediatric hepatology and clinical trials.

Articles

Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

2024

ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

2024

Real-world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

2024

Impact of early immunosuppression on pediatric liver transplant outcomes within 1 year

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

2024

Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

LANCET GASTROENTEROLOGY & HEPATOLOGY

2024

Wilson disease: a summary of the updated AASLD Practice Guidance

HEPATOLOGY COMMUNICATIONS

2023

MONITORING MAINTENANCE THERAPY WITH D-PENICILLAMINE FOR WILSON'S DISEASE: LESSONS FROM SCREENING FOR A RANDOMIZED TRIAL

GUT

2023

PATTERNS OF ALT, AST AND 24-HOUR URINE COPPER IN ADULT PATIENTS WITH TREATED WILSON DISEASE: RESULTS FROM AN INTERNATIONAL MULTI-SITE REGISTRY AT ENROLMENT AND OVER THE COURSE OF 3 YEARS

GUT

2023

Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study

HEPATOLOGY COMMUNICATIONS

2023

North American Biliary Stricture Management Strategies in Children After Liver Transplantation: A Multicenter Analysis From the Society of Pediatric Liver Transplantation (SPLIT) Registry

LIVER TRANSPLANTATION

2022

Education & Training

Education

Universidad Central Del Este

Residency

John H. Stroger, Jr, Hospital of Cook County - Graduate Education
Cook County Health

Fellowship

University of Florida
University of Florida - College of Medicine

Board Certifications

American Board of Pediatrics

Associated Clinical Trials

NCT05470985

A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active Crohn’s Disease with an Inadequate Response to Conventional Therapy

Icon for trial | IM047023 A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active Crohn’s Disease with an

The purpose of this study is to see whether ozanimod (RPC1063, also referred to as the ‘study drug’ or ‘study treatment’) is safe and effective for the possible treatment of Crohn’s Disease (CD) in a pediatric population. To do ...